Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 17, 2011, Pages 2035-2041

  Kayhan, Servet ^a,b   Akgünesws ̧, Alper ^a,b  

^a Samsun Chest Diseases and Thoracic Surgery Hospital   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

Author keywords

Ethambutol; Isoniazid; Pyrazinamide; Rifampicin; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

CREATININE; ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SERUM ALBUMIN;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; BODY MASS; CIGARETTE SMOKING; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MALE; PATIENT COMPLIANCE; PREVALENCE; PROTEIN BLOOD LEVEL; RELAPSE; TREATMENT OUTCOME; VENOUS BLOOD;

EID: 81155139174     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP11.511     Document Type: Article

References (21)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN (2003) American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med., 167: 603-62.
2. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, (2008). Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis., 27: 467-72.
3. Cockroft DW, Gault MH (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16:31-41.
4. Diacon AH, Patientia R, Venter A, van Helden PD, Smith PJ, McIlleron H (2007). Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother., 51: 2994-6.
5. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S (2011). Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center. Chemotherapy, 57: 7-11.
6. Heysell SK, Moore JL, Keller SJ, Houpt ER (2010). Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg. Infect. Dis., 16: 1546-53.
7. Holdiness MR (1984). Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet., 9: 511-514.
8. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE (2009). Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy, 29: 503-510.
9. Jeon CY, Murray MB (2008). Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med., 5: e152.
10. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE (1998). Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest, 113: 1178-1183.
11. Mcllleron H, Wash P, Burger A, Norman J, Folb PI, Smith P (2006). Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother., 50: 1170-1177.
12. Mehta JB, Shantaveerapa H, Byrd RPJ, Morton SE, Fountain F, Roy TM (2001). Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest, 120: 1520-1524.
13. Moussa LA, Khassouani CE, Soulaymani R, Jana M, Cassanas G, Alric R, Hue B (2002). Therapeutic isoniazid monitoring using a simple high performance liquid chromatographic method with ultraviolet detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 766: 181-187.
14. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, Ashkin D (2001). Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, HIV status, and other risk factors. Clin. Infect. Dis., 32: 515-517.
15. Peloquin CA (2002). Theapeutic drug monitoring in the treatment of tuberculosis. Drugs, 62: 2169-2183.
16. Peloquin CA, MacPhee AA, Berning SE (1993). Malabsorption of antimycobacterial medications. N. Eng. J. Med., 329: 1122-1123.
17. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME (1996). Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother, 30: 919-25.
18. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rostomjee R, Levin J (2005). The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med., 172: 128-35.
19. Tappero JW, Bradford WZ, AgertonTB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, MoffatHJ, Peloquin CA (2005). Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis., 41: 461-469.
20. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH (2007). Low serum concentrations of antituberculosis drugs and determinants of their serum levels. Int. J. Tuberc. Lung Dis., 11: 972-978.
21. WHO (2010). global report on surveillance and response. Geneva, World Health Organization, 2010 (WHO/HTM/TB/2010-3).